SARB2C: Substance Abuse Research from the Bench to Community Group

Facilitated by Linda Cottler
lbcottler@ufl.edu

  1. What is the SAR-B2C Group? SAR-B2C is a group of investigators and students at UF with a focus on translational science regarding T0 to T4 substance use and addiction research. The group meets monthly to share ideas that focus on collaborative research initiatives. Given the national opioid epidemic, and other drug use on the rise, there is an explicit need for translational research, and training the next generation of scientists, in this important area.
    • Florida is 3rd most populous state in the US; 20% of the population is 65 years of age and older, Florida is unique in that medical examiners, Department of Health (DOH), Department of Children and Families (DCF), the Sheriff’s Office, Fire and Rescue, Safety Net agencies, are well-integrated and well-coordinated.
    • Given the national opioid epidemic, in particular, there is an explicit need to train public health oriented scientists and clinicians from the bench to community who can collaborate on effective strategies for treatment and prevention.
    • Contribution to science
      • Numerous publications both past and recent in the areas of the epidemiology of opioid use, misuse, dependence, ED (emergency department) utilization for opioid use, pain and opioids, drug development, Prescription Drug Monitoring Program (PDMP), prevention of opioid use among the community, Neonatalabstinence syndrome (NAS), disposal of opioid pills, harm reduction research, forensics, policy evaluation, medical examiner data, and comorbidities.
      • History of significant—the National Institute on Drug Abuse (NIDA) funding (past and current) from all divisions of NIDA indicating breadth and depth of research funding.
      • Significant leadership with NIDA, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Office of National Drug Control Policy (ONDCP), College on Problems of Drug Dependence (CPDD), Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), DOH, World Health Organization (WHO), Diagnostic and Statistical Manual of Mental Disorders (DSM), International Classification of Diseases (ICD), Behavior, Biology and Chemistry (BBC).
      • Current Clinical and Translational Science Award (CTSA) KL2 scholar, Dr. Henry Young is an ED physician (former NIDA T32 post doc) and is developing program of research for UF EDs.
      • Team of individuals from professors to NIDA fellows from 6 UF Colleges spanning T0 to T4 translational areas.
    • Sources of data for primary and secondary analyses of opioid use
      • Site for the national Opioid Post-Marketing Requirement (PMR) Consortium (OPC) Longitudinal and Cross-Sectional Medication Use Safety Evidence Study (MUSE)
      • Ongoing community cohort of 11,000 members from 51 Florida counties (14% past-30-day prescription pain pill users and >50% lifetime prescription pain pill use with permission to recontact)
      • 650 retired NFL players screened for opioid use, with permission to recontact
      • 11,048 youth 10-18 years of age (secondary database)
      • OneFlorida Clinical Consortium (ongoing claims data and HER with 15M lives)
      • Florida Prescription Drug Monitoring Program (PDMP)
      • Pharmacogenetics data
      • FROST data (https://frost.med.ufl.edu/) – come from medical examiners looking at overdoses by drug from 2005-2016, and continuously updating going forward
        • Including epidemiologic indicators
        • Data on an interactive map that anyone can analyze
      • Claims data
        • Medicaid – 13 years, 100 million people, 29 states
        • Privately insured – 11 years, 80 million people
      • ABCD (Adolescent Brain Cognitive Development study) data
      • https://epidemiology.phhp.ufl.edu/wordpress/wp-admin/profile.php

      • NIDA smokescreen chip data
  2. What opportunities exist to participate in addressing the specific research areas?
    • Access to patients throughout Florida
    • Access to community members
      • Florida has been impacted by opioids significantly more than most other states in the nation
      • HealthStreet – unique community engagement program
    • ABCD study site
    • MUSE national study site
    • Access to NFL players who have been assessed previously
    • Access to ER/LA (extended release/long acting) users (MUSE study)
    • Members of Alachua County Opiate Task Force with Sheriff’s Office, DOH, Fire Rescue, UF
    • OD (Overdose) surveillance
    • Access to 5,000 Deterra Deactivation Pouches to distribute to the community
    • International expert in toxicology/forensics/medico-legal death investigation
    • Pain Research and Intervention Center of Excellence (PRICE)
    • NIDA funded Substance Abuse Module assessment for DSM 5 substance use disorders
    • OD study in West Virginia (CDC-funded)
    • Members of Opiate Task Force for Alachua County
    • 54k students at UF
    • Rural areas surrounding UF (9 counties)
    • Experienced basic, clinical, epidemiological and policy-focused investigators
    • Consent2Share (UF Health patients are asked to participate in research)
      • 407k in Gainesville and 290k in Jacksonville who have had an opioid prescription
    • Text messaging protocols
    • FDA adverse events expertise
    • Geo-spatial expertise
    • Trained and certified Community Health Workers (CHWs)
    • Site for NCATS CTSA
    • Pharmacoepidemiologists
    • UF Health Cancer Center
    • Center for Addiction Research & Education (CARE)
    • Clinical Research Internship Study Program (CRISP)
    • Southern HIV & Alcohol Research Consortium (SHARC) https://sharc-research.org/
    • Resource Centers for Minority Aging Research(RCMAR)
    • Pepper Center
    • Institute on Aging
    • McKnight Brain Institute
    • Genetics Institute
    • Study of Teen Opioid Misuse and Prevention (STOMP) Lab
    • Addiction Treatment Program and Florida Recovery Center
    • Well-established community engagement program with CHWs, volunteers, and staff
    • Very strong NIDA-funded basic science initiatives
    • Home of a NIDA T32 focused on prevention and public health consequences of substance abuse (Director LB Cottler) and an NIA T32 focused on aging and pain (Director R Fillingim)
    • Host site for “Our Community, Our Health”: a monthly national town hall meeting to disseminate research findings
    • Lake Nona –Center for Pharmacometrics and Systems Pharmacology
    • CTSA Translational Drug Development Core
    • Family Medicine Department pain management training program (may be the only one in the US)
  3. What are action oriented next steps your pod or other CTSA Program groups could take to move participation in the NIH Opioid Research Initiative forward?
    • R13 conference meeting
      • Focus on T0-T4 studies related to opioid use, prevention, epidemiology, back translational studies, drug discovery for alternatives to opioids, and medicinal chemistry
      • Hosting meetings with other CTSAs to discuss our ideas and plans for future grant submission
    • CTSA symposium with site members at CPDD, BBC, or Society for Prevention Research
  4. What can the CTSA Program Consortium do to train the next generation of researchers?
    • Get NIDA/other NIH T32 directors together who are also CTSA members
    • Have NIDA sponsor a national meeting with fellows and NIDA/other NIH T32 directors
      • Fellows will be exposed to collaborative research
    • Online seminar hosted by NIDA to disseminate on a regular basis the latest research
    • Funding new investigators, fellows, graduate students, and post-docs
      • A certain percentage of CTSI pilot grants could be set aside for opioid research conducted by new investigators
    • Fund more junior faculty
    • More K awards
    • Translational workforce development
      • Develop and train more clinician researchers

The SARB2C Group consists of the following people along with their 2018-19 publications related to opioids: